Development Pipeline

DNX-2401 (Tasadenoturev)

DNX-2401 for Recurrent Glioblastoma
Combined with Pembrolizumab (Keytruda®)*
DNX-2401 for Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Monotherapy for Pediatric Patients

Armed Viruses

DNX-2440 for Recurrent Glioblastoma
DNX-2440 for Solid Tumors
DNX-2450 for Solid Tumors

Myxoma Virus

MYX-135 for Hematological Malignancies

DNX-2401 (Tasadenoturev)

DNX-2401 is an oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. To accomplish this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from pre-clinical and clinical studies indicate that DNX-2401 (1) replicates in human tumors (2) elicits tumor necrosis (3) triggers intratumoral immune cell infiltration, and (4) can lead to long term tumor destruction. DNX-2401 has been granted PRIME and Orphan designation by the EMA and Fast Track and Orphan designation by the FDA.

learn about DNX-2401 clinical trials >


Armed with OX40L

DNX-2440 is the next generation virus in DNAtrix’s adenovirus platform and is in development for a variety of tumor indications. It combines the virus backbone of DNX-2401 with the expression of OX40 ligand (OX40L), a powerful costimulatory molecule known to enhance immune responses directed to tumors.

learn more about DNX-2440 clinical trials >


Armed with undisclosed t-cell stimulator

DNX-2450 is an Armed Virus in development for solid tumors. It combines the clinically effective and safe viral backbone of DNX-2401 with the expression of an undisclosed T-cell stimulator that can enhance antitumor immunity.


MYX-135 is a novel oncolytic immunotherapy designed to treat hematological malignancies after myeloablative chemotherapy. MYX-135 is a myxoma virus that cannot infect normal human cells but destroys cancer cells with high efficiency.